<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407431</url>
  </required_header>
  <id_info>
    <org_study_id>EXT15030529 CDRN-1306-04912</org_study_id>
    <nct_id>NCT02407431</nct_id>
  </id_info>
  <brief_title>PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort</brief_title>
  <official_title>PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical&#xD;
      data from electronic health records (EHR) and patient reported outcomes (PRO) to answer&#xD;
      questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers,&#xD;
      and other stakeholders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to create the PaTH Network IPF Clinician-Patient Partnership Cohort,&#xD;
      which will allow the conduct of patient-centered observational studies on IPF across the&#xD;
      multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of&#xD;
      the PaTH network. Creating the IPF Clinician-Patient Partnership Cohort will involve:&#xD;
&#xD;
        1. Recruiting patients with IPF to participate in the PaTH Network IPF Clinician-Patient&#xD;
           Partnership Cohort&#xD;
&#xD;
        2. Administering surveys to the IPF Clinician-Patient Partnership Cohort approximately&#xD;
           every 3 months to collect patient reported outcomes (PROs)&#xD;
&#xD;
        3. Merging individual patient health record data into the IPF Clinician-Patient Partnership&#xD;
           Cohort database&#xD;
&#xD;
        4. Tracking whether the patient participant has biospecimens in a PaTH site biorepository&#xD;
           and prepare for possible sharing of biospecimens in future studies.&#xD;
&#xD;
        5. Determining if an automated procedure for identifying duplicate patients across PaTH&#xD;
           institutions without the use of protected health information (PHI) is valid compared to&#xD;
           a manual matching procedure using PHI.&#xD;
&#xD;
        6. Identifying potential participants for future research studies.&#xD;
&#xD;
      The secondary objectives are to use the PaTH Network IPF Clinician-Patient Partnership Cohort&#xD;
      to answer patient-centered research questions including:&#xD;
&#xD;
        1. What is the prevalence of gastroesophageal reflux disease (GERD) in IPF, and what effect&#xD;
           does GERD and its treatment have on IPF disease progression, quality of life, and&#xD;
           survival?&#xD;
&#xD;
        2. What is the association of oxygen use with survival, quality of life, exercise&#xD;
           tolerance, neurocognitive function, and dyspnea?&#xD;
&#xD;
        3. How often do IPF patients have advance directives, how often are advance directives&#xD;
           documented in the electronic health record, and does having an advance directive&#xD;
           influence how/where IPF patients die, their health care utilization, satisfaction with&#xD;
           care, and quality of life?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Create PaTH Network IPF Clinician-Patient Partnership Cohort</measure>
    <time_frame>18 months</time_frame>
    <description>Create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The target study population is adults with IPF who receive health care at one of the PaTH&#xD;
        Network institutions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The target study population is adults identified as having IPF (through the PaTH IPF&#xD;
             computable phenotype algorithm or a local IPF registry).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Deceased&#xD;
&#xD;
          -  Not proficient in English&#xD;
&#xD;
          -  Has not had at least one outpatient encounter in the past 18 months at the PaTH health&#xD;
             system's pulmonary specialty clinic through which they are recruited&#xD;
&#xD;
          -  Lung transplant&#xD;
&#xD;
          -  Already enrolled in the PaTH Clinician-Patient Partnership Cohort at another PaTH&#xD;
             institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen McTigue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jody McCullough</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anuradha Paranjape</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kathleen McTigue</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

